These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 157413)
1. The pathogensis and medical treatment of extrapyramidal disease. Calne DB; Eisler T Med Clin North Am; 1979 Jul; 63(4):715-27. PubMed ID: 157413 [No Abstract] [Full Text] [Related]
2. Approaches to the study of cerebral dopamine metabolism in certain extrapyramidal diseases. Barkhatova VP; Kandel' EI; Demina EG Neurosci Behav Physiol; 1985; 15(2):132-9. PubMed ID: 3160969 [No Abstract] [Full Text] [Related]
3. [Neuraminergic conception of extrapyramidal syndromology]. Levin SL Zh Nevropatol Psikhiatr Im S S Korsakova; 1977; 77(2):293-9. PubMed ID: 139066 [No Abstract] [Full Text] [Related]
4. Biochemical mechanisms and management of choreiform movement disorders. de Silva L Drugs; 1977 Oct; 14(4):300-10. PubMed ID: 144049 [No Abstract] [Full Text] [Related]
6. Movement disorders in the psychiatric patient. Moros DA; Yahr MD Hosp Community Psychiatry; 1984 Apr; 35(4):377-83. PubMed ID: 6232196 [TBL] [Abstract][Full Text] [Related]
7. [Nigrostriatal system as a source of torsion extrapyramidal disorders (review)]. Arushanian EB; Dutov AA Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(6):930-8. PubMed ID: 6774537 [No Abstract] [Full Text] [Related]
8. The pharmacology of extrapyramidal movement disorders. Klawans HL Monogr Neural Sci; 1973; 2():1-136. PubMed ID: 4271860 [No Abstract] [Full Text] [Related]
9. Chapter 33: the history of movement disorders. Lanska DJ Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136 [TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease and levodopa. A five-year follow-up and review. Markham CH; Treciokas LJ; Diamond SG West J Med; 1974 Sep; 121(3):188-206. PubMed ID: 4606887 [No Abstract] [Full Text] [Related]
11. Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei. Wolfarth S Pol J Pharmacol Pharm; 1976; 28(5):469-93. PubMed ID: 796834 [No Abstract] [Full Text] [Related]
12. Drug treatment of diseases characterized by abnormal movements. Marsden CD Proc R Soc Med; 1973 Sep; 66(9):871-3. PubMed ID: 4281483 [No Abstract] [Full Text] [Related]
13. Analysis of abnormal voluntary and involuntary movements with surface electromyography. Hallett M Adv Neurol; 1983; 39():907-14. PubMed ID: 6660128 [No Abstract] [Full Text] [Related]
14. Current concepts in the management of movement disorders. Olanow CW Clin Neurosurg; 1981; 28():137-70. PubMed ID: 6119175 [No Abstract] [Full Text] [Related]
17. [Physiology and pharmacology of extrapyramidal tract]. Yoshida M; Mizuno Y Nihon Rinsho; 1975 Oct; 33(10):2964-77. PubMed ID: 128646 [No Abstract] [Full Text] [Related]
18. Diseases of the central nervous system. Involuntary movements. Mawdsley C Br Med J; 1975 Dec; 4(5996):572-4. PubMed ID: 1203674 [No Abstract] [Full Text] [Related]
19. Involuntary movement disorders. Still CN Neurol Clin; 1984 Feb; 2(1):71-89. PubMed ID: 6239089 [TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography in movement disorders. Martin WR Can J Neurol Sci; 1985 Feb; 12(1):6-10. PubMed ID: 3156662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]